Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | GRK2 | P25098 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25824651 | 0.80 | L3MBTL1 (0.63) | NPC1RAB9AGAA | |
| SCHEMBL2207003 | 0.80 | TAAR1 (0.62) | SIRT2NPC1RAB9A | |
| SCHEMBL17912866 | 0.78 | NPC1 (0.60) | SIRT2NPC1RAB9AGAADRD2 | |
| SCHEMBL920873 | 0.77 | NPC1 (0.56) | F2SIRT2NPC1RAB9A | |
| SCHEMBL3426124 | 0.76 | SIRT2 (0.59) | SIRT2RAB9ANR1H4 | |
| SCHEMBL25822204 | 0.76 | GAA (0.54) | SIRT2NPC1RAB9AGAADRD2 | |
| SCHEMBL2208821 | 0.76 | MAOA (0.52) | NPC1RAB9ADRD2DRD4DRD3 | |
| SCHEMBL10065543 | 0.75 | F2 (0.62) | F2ROCK2RAB9AGAA | |
| SCHEMBL611324 | 0.73 | TAAR1 (0.62) | NPC1RAB9A | |
| SCHEMBL6057426 | 0.73 | MAOB (0.69) | SIRT2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | F2 4830/4885SIRT2 903/4885ROCK2 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.